Well-Differentiated Hand Liposarcoma with Bone Metastases Treated Successfully with Zoledronic Acid

被引:2
作者
Mystakidou, Kyriaki [1 ]
Panagiotou, Irene [1 ]
Brountzos, Elias [2 ]
Kouloulias, Vassilios [2 ]
Gouliamos, Athanasios [1 ]
机构
[1] Univ Athens, Sch Med, Pain Relief & Palliat Care Unit, Dept Radiol 1,Arete Hosp, Athens 11526, Greece
[2] Univ Athens, Sch Med, Attikon Univ Hosp, Dept Radiol 2, Athens 11526, Greece
来源
ONKOLOGIE | 2011年 / 34卷 / 12期
关键词
Liposarcomas; Bone metastases; Local recurrence; Bisphosphonates; Zoledronic acid; CONSERVATION SURGERY; MYXOID LIPOSARCOMA; LUNG-CANCER; THERAPY; BISPHOSPHONATES; SURVIVAL; SARCOMA; GROWTH; TUMORS; CELLS;
D O I
10.1159/000334551
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Well-differentiated liposarcomas of the upper extremities, such as the hand or forearm, are extremely rare and are commonly misdiagnosed and considered benign. They are frequently reported as having low metastatic potential. Case Report: We report the case of a 58-year-old man with well-differentiated hand liposarcoma and diffuse bone metastases. The patient initially presented with a tumor of the thenar eminence and was treated with marginal surgical excision and external beam irradiation. 4 months after this treatment, soft tissue local recurrence and skeletal metastases were detected. Zoledronic acid treatment (4 mg per month) was initiated, and both the tumor and the metastases regressed. The patient remains cancer-free 3.5 years after diagnosis of the metastatic disease. Conclusion: Significant metastatic disease can develop in patients with well-differentiated liposarcomas. The beneficial effect of zoledronic acid observed in this case may be related to its anticancer properties, as described in phase III trials in various tumor types.
引用
收藏
页码:706 / 709
页数:4
相关论文
共 50 条
  • [31] Resection Status Does Not Impact Recurrence in Well-Differentiated Liposarcoma of the Extremity
    Olson, Chelsea R.
    Suarez-Kelly, Lorena P.
    Ethun, Cecilia G.
    Shelby, Rita D.
    Yu, Peter Y.
    Hughes, Tasha M.
    Palettas, Marilly
    Tran, Thuy B.
    Poultsides, George
    Tseng, Jennifer
    Roggin, Kevin K.
    Chouliaras, Konstantinos
    Votanopoulos, Konstantinos
    Krasnick, Bradley A.
    Fields, Ryan C.
    King, David M.
    Bedi, Meena
    Pollock, Raphael E.
    Grignol, Valerie P.
    Cardona, Kenneth
    Howard, J. Harrison
    AMERICAN SURGEON, 2021, 87 (11) : 1752 - 1759
  • [32] The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid
    Oh, William K.
    Proctor, Kevin
    Nakabayashi, Mari
    Evan, Carolyn
    Tormey, Lauren K.
    Daskivich, Timothy
    Antras, Lucia
    Smith, Michael
    Neary, Maureen P.
    Duh, Mei Sheng
    CANCER, 2007, 109 (06) : 1090 - 1096
  • [33] Prospective Evaluation of Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma
    Orita, Yorihisa
    Sugitani, Iwao
    Takao, Soshi
    Toda, Kazuhisa
    Manabe, Jun
    Miyata, Satoshi
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (12) : 4008 - 4013
  • [34] Prospective Evaluation of Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma
    Yorihisa Orita
    Iwao Sugitani
    Soshi Takao
    Kazuhisa Toda
    Jun Manabe
    Satoshi Miyata
    Annals of Surgical Oncology, 2015, 22 : 4008 - 4013
  • [35] Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases
    Leto, G
    Badalamenti, G
    Arcara, C
    Crescimanno, M
    Flandina, C
    Tumminello, FM
    Incorvaia, L
    Gebbia, N
    Fulfaro, F
    ANTICANCER RESEARCH, 2006, 26 (1A) : 23 - 26
  • [36] Prostate Cancer Presenting with Normal Serum PSA Levels and Boney Metastases Treated with Zoledronic Acid
    Mystakidou, Kyriaki
    Katsouda, Emmanuela
    Parpa, Efi
    Vlavos, Lambros
    JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY, 2005, 19 (03) : 41 - 45
  • [37] Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics
    Lipton, A.
    Fizazi, K.
    Stopeck, A. T.
    Henry, D. H.
    Smith, M. R.
    Shore, N.
    Martin, M.
    Vadhan-Raj, S.
    Brown, J. E.
    Richardson, G. E.
    Saad, F.
    Yardley, D. A.
    Zhou, K.
    Balakumaran, A.
    Braun, A.
    EUROPEAN JOURNAL OF CANCER, 2016, 53 : 75 - 83
  • [38] Lymphocyte Composition and Distribution in Inflammatory, Well-differentiated Retroperitoneal Liposarcoma: Clues to a Potential Adaptive Immune Response and Therapeutic Implications
    Tseng, William W.
    Demicco, Elizabeth G.
    Lazar, Alexander J.
    Lev, Dina C.
    Pollock, Raphael E.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2012, 36 (06) : 941 - 944
  • [39] Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases
    Koo, Kaitlin
    Lam, Kinsey
    Mittmann, Nicole
    Konski, Andre
    Dennis, Kristopher
    Zeng, Liang
    Lam, Henry
    Chow, Edward
    SUPPORTIVE CARE IN CANCER, 2013, 21 (06) : 1785 - 1791
  • [40] Is compartmental surgery always mandatory in retroperitoneal liposarcoma? A case report of multifocal synchronous well-differentiated liposarcoma
    Brisinda, Giuseppe
    Chiarello, Maria Michela
    ANNALI ITALIANI DI CHIRURGIA, 2021, 92 (04) : 419 - 423